Furthermore, Pitrakinra, a competitive antagonist against the IL-4/IL-13 receptor, mainly treats asthma and allergic diseases by competitively binding the IL-12 receptor, mitigating the effects of IL-4 and IL-13, and easing airway inflammation. This evidence concerns the gene IL4 and asthma.